Abbott India Limited Q2 FY27 Profit Rises 9% to ₹453 Crore

Abbott India Limited reported profit after tax of ₹453.45 crore for the quarter ended September 30, 2026, up 9.2% from ₹415.27 crore a year earlier, while total income increased to ₹2,019.07 crore from ₹1,889.05 crore and its board approved the unaudited Q2 and half-year FY27 results on November 5, 2026.

What did Abbott India report for Q2 FY27?

Abbott India reported total income of ₹2,019.07 crore and profit after tax of ₹453.45 crore for Q2 FY27. The quarter covers the three months ended September 30, 2026, and the results were approved by the board at its meeting held on November 5, 2026.

Total income increased by ₹130.02 crore from ₹1,889.05 crore in the corresponding quarter of the prior year. Profit after tax rose by ₹38.18 crore from ₹415.27 crore. The reported profit growth was higher than the increase in total income, although the disclosed information does not provide a separate EBITDA figure or margin details.

What did Abbott India’s board approve on November 5?

Abbott India’s board approved the unaudited financial results for the quarter and six months ended September 30, 2026. The company had previously informed BSE that its board would meet on November 5 to consider the Q2 and first-half FY27 results.

The results were accompanied by a Limited Review Report from statutory auditor Walker Chandiok & Co. LLP. According to the disclosed outcome, the report contained no qualifications. This review is part of the reporting process for unaudited quarterly and half-yearly financial statements of listed companies.

The advance board-meeting notice did not contain financial figures. The subsequent board outcome provided the reported income and profit figures for the September quarter and the six-month period.

How did Abbott India perform in the first half of FY27?

Abbott India reported total income of ₹3,908.12 crore and profit after tax of ₹881.97 crore for the six months ended September 30, 2026. These figures include the company’s results for the June and September quarters of FY27.

For Q1 FY27, Abbott India had reported revenue from operations of ₹1,814 crore and net profit of ₹428.5 crore. The company’s Q1 net profit was stated to be 17.1% higher year-on-year, while revenue from operations rose 4.3% year-on-year.

The company’s disclosures use total income in the Q2 result summary and revenue from operations in the Q1 update. These are separate reported line items, so they should not be treated as directly interchangeable without the detailed financial statements.

Why do the Q2 results matter for Abbott India investors?

The Q2 disclosure gives investors the latest reported measure of Abbott India’s earnings and income performance after the company’s November 5 board meeting. Profit after tax rose 9.2% year-on-year in the September quarter, while total income increased 6.9% from the corresponding prior-year period.

Before the result announcement, market commentary had focused on whether profit growth could remain ahead of topline growth, following Q1 FY27. That commentary had referred to expectations around revenue growth, profitability and margins, but it was not company guidance. Abbott India has not disclosed formal FY27 guidance in the material provided.

Investors will therefore need to rely on the detailed result statement and future company disclosures for information on product mix, expenses, margins, segment performance or pricing. None of these details were included in the supplied board-meeting outcome.

What reporting and compliance steps accompanied the results?

Abbott India followed its scheduled reporting process by convening its board to approve the September-quarter and first-half results. The company had also communicated the board meeting date to BSE in advance, identifying the agenda as approval of unaudited Q2 and H1 FY27 financial results.

The company closed its insider trading window effective October 1, 2026, in connection with the Q2 result process, according to the information provided. Such trading-window restrictions are intended to support compliance with SEBI regulations around unpublished price-sensitive information during financial reporting periods.

The auditor’s unqualified limited review is another relevant disclosure for shareholders. It indicates that the statutory auditor’s limited review report, as submitted with the unaudited results, did not contain qualifications.

Conclusion

Abbott India’s Q2 FY27 results showed a year-on-year increase in both total income and profit after tax. Total income rose to ₹2,019.07 crore, while profit after tax reached ₹453.45 crore, and the company reported H1 FY27 profit after tax of ₹881.97 crore.

The next disclosures to watch are Abbott India’s detailed financial statements and subsequent quarterly updates, which may provide further information on operating costs, margins and product-level performance. The supplied information does not disclose a formal FY27 guidance target or a future financial event beyond the completed November 5 board meeting.